These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33909895)

  • 1. Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis.
    Ahmed F; Maclean RH; Nihtyanova SI; Ong VH; Murray CD; Denton CP
    Rheumatology (Oxford); 2022 Feb; 61(2):781-786. PubMed ID: 33909895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-sectional study using the University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0 (UCLA SCTC GIT 2.0) for gastrointestinal disorders of systemic sclerosis.
    Hisada S; Takeuchi S; Tozawa T; Yamada Y; Ito Y; Kodera M
    J Dermatol; 2024 Oct; 51(10):1329-1334. PubMed ID: 38963343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
    Hamaguchi Y
    J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes.
    Clark KEN; Campochiaro C; Host LV; Sari A; Harvey J; Denton CP; Ong VH
    Sci Rep; 2022 Jul; 12(1):11212. PubMed ID: 35780179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies in systemic sclerosis overlap syndrome and their correlation with organ damage and survival.
    Wang F; Li C; Li X; Li S; Jia Y
    Ann Med; 2024 Dec; 56(1):2407526. PubMed ID: 39348269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
    Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C
    Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
    Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.
    Bodukam V; Hays RD; Maranian P; Furst DE; Seibold JR; Impens A; Mayes MD; Clements PJ; Khanna D
    Rheumatology (Oxford); 2011 Feb; 50(2):330-4. PubMed ID: 20884655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Relationship Between Autonomic Dysfunction of the Gastrointestinal Tract and Emotional Distress in Patients With Systemic Sclerosis.
    DiRenzo D; Russell J; Bingham CO; McMahan Z
    J Clin Rheumatol; 2021 Jan; 27(1):11-17. PubMed ID: 31524844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies.
    Markusse IM; Meijs J; de Boer B; Bakker JA; Schippers HPC; Schouffoer AA; Ajmone Marsan N; Kroft LJM; Ninaber MK; Huizinga TWJ; de Vries-Bouwstra JK
    Rheumatology (Oxford); 2017 Jul; 56(7):1081-1088. PubMed ID: 27940596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Autoantibodies and their clinical characteristics in systemic sclerosis].
    Hamaguchi Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(3):139-47. PubMed ID: 23812071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests.
    Alkema W; Koenen H; Kersten BE; Kaffa C; Dinnissen JWB; Damoiseaux JGMC; Joosten I; Driessen-Diks S; van der Molen RG; Vonk MC; Smeets RL
    Autoimmunity; 2021 May; 54(3):148-155. PubMed ID: 33818234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis.
    Bae S; Allanore Y; Furst DE; Bodukam V; Coustet B; Morgaceva O; Maranian P; Khanna D
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):57-63. PubMed ID: 23910611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
    Baron M; Hudson M; Steele R; Lo E;
    J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies as predictive tools in systemic sclerosis.
    Nihtyanova SI; Denton CP
    Nat Rev Rheumatol; 2010 Feb; 6(2):112-6. PubMed ID: 20125179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
    Nagaraja V; Hays RD; Khanna PP; Spiegel BM; Chang L; Melmed GY; Bolus R; Khanna D
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1725-30. PubMed ID: 24692332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-RNPC-3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate-to-Severe Gastrointestinal Dysmotility.
    McMahan ZH; Domsic RT; Zhu L; Medsger TA; Casciola-Rosen L; Shah AA
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1164-1170. PubMed ID: 30242973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies.
    Nakane S; Umeda M; Kawashiri SY; Mukaino A; Ichinose K; Higuchi O; Maeda Y; Nakamura H; Matsuo H; Kawakami A
    Arthritis Res Ther; 2020 Feb; 22(1):32. PubMed ID: 32085768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
    Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort.
    Lazzaroni MG; Marasco E; Campochiaro C; DeVries-Bouwstra J; Gonzalez-Perez MI; Rojas-Serrano J; Hachulla E; Zanatta E; Barsotti S; Furini F; Triantafyllias K; Abignano G; Truchetet ME; De Luca G; De Langhe E; Hesselstrand R; Ingegnoli F; Bertoldo E; Smith V; Bellando-Randone S; Poormoghim H; Colombo E; Ceribelli A; Furloni A; Zingarelli S; Cavazzana I; Franceschini F; Del Galdo F; Denton CP; Cavagna L; Distler O; Allanore Y; Airò P;
    Rheumatology (Oxford); 2021 Nov; 60(11):5028-5041. PubMed ID: 33580257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.